Home  /  Resource Library  /  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Results of phase II study showed Pembrolizumab was associated with high response rates and an acceptable safety profile in patients with relapsed/refractory Hodgkin